Easter Sale – 70% Off TipRanks
Bioxcel Therapeutics ( (BTAI) ) just unveiled an update.
On March 10, 2026, BioXcel Therapeutics, Inc. entered into a securities purchase agreement for a registered direct offering of 2,480,294 shares of common stock with accompanying warrants, as well as pre-funded warrants for up to 2,020,491 additional shares with accompanying warrants, at combined offering prices of $1.739 and $1.738, respectively. The offering, which closed on March 11, 2026, generated approximately $7.8 million in gross proceeds before fees, with Rodman & Renshaw LLC acting as exclusive placement agent and receiving a 6.0% cash fee, warrants equal to 4.0% of the shares placed, and reimbursement of specified expenses.
As part of the same transaction, BioXcel entered into a warrant amendment agreement on March 10, 2026, reducing the exercise price of certain warrants issued in March and November 2024 to $1.614 per share and extending their term to five years after the offering’s closing. The investor paid about $173,135 for this repricing and extension, and the company paid the placement agent a 6.0% cash fee on the warrant amendment proceeds, reflecting BioXcel’s continued reliance on structured equity and warrant-based financing to bolster its balance sheet and maintain access to capital markets.
The most recent analyst rating on (BTAI) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Bioxcel Therapeutics stock, see the BTAI Stock Forecast page.
Spark’s Take on BTAI Stock
According to Spark, TipRanks’ AI Analyst, BTAI is a Neutral.
The score is held down primarily by very weak financial performance (ongoing large losses, heavy cash burn, negative equity and high debt). Technical indicators are mixed and do not confirm a strong uptrend, while valuation lacks support due to negative earnings and no dividend. Offsetting factors include constructive corporate catalysts around IGALMI’s potential at-home label expansion and supportive clinical data.
To see Spark’s full report on BTAI stock, click here.
More about Bioxcel Therapeutics
BioXcel Therapeutics, Inc. is a biopharmaceutical company that operates in the life sciences industry. The company focuses on developing and commercializing therapeutics, with its capital-raising activities centered on issuing common stock and various classes of warrants to support its operations and strategic initiatives in the healthcare market.
Average Trading Volume: 1,354,222
Technical Sentiment Signal: Sell
Current Market Cap: $33.9M
See more insights into BTAI stock on TipRanks’ Stock Analysis page.